Tokyo-based Astellas Pharma is reorganizing its drug discovery research functions.
Among the changes will be the creation of the Bioimaging Research Labs, which will carry out research and development projects by using bioimaging technologies, such as PET, MRI and CT. The labs will promote the efficacy study, the synthesis of labeled compounds for new drug candidates, the development of automated apparatus for synthesis of PET tracers, disease model animals and the support of clinical studies using bioimaging technologies.
Astellas also will reorganize the fermentation research functions of its Tsukuba Research Center at Tokyo Institute of Technology. The fermentation discovery research functions of the Fermentation Research Labs will be transferred to the Pharmacology Research Labs and the Molecular Medicine Research Labs and the Fermentation Research Labs will be dissolved.
Drug discovery functions at Tsukuba Research Center will be transferred to Tsukuba Research Center at Astellas' Miyukigaoka R &D Center, the firm said.